SGLT2 Inhibitors Beyond Glycemic Control: Emerging Therapeutic Applications, Clinical Evidence, Safety and Future Perspectives

Type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD), heart failure (HF) and chronic kidney disease (CKD) are closely interconnected chronic disorders that contribute substantially to morbidity, mortality and healthcare utilization worldwide. Traditionally, pharmacotherapy for T2DM focused primarily on achieving glycemic targets and preventing microvascular and macrovascular complications. However, the modern approach to diabetes pharmacotherapy increasingly emphasizes cardiovascular, renal, metabolic and weight-related outcomes in addition to glycemic control.

Sodium-glucose cotransporter 2 (SGLT2) inhibitors represent one of the most important developments in this transition. The first members of this class were introduced as glucose-lowering drugs based on their ability to inhibit glucose reabsorption in the proximal renal tubule. By promoting urinary glucose excretion, these drugs reduce plasma glucose concentrations independently of insulin secretion or insulin sensitivity.

The initial cardiovascular outcome trials produced an unexpected and clinically important observation: SGLT2 inhibitors could reduce hospitalization for heart failure and influence renal outcomes beyond what would be expected from their modest glucose-lowering effects. Subsequent dedicated trials in heart failure and CKD populations confirmed that their therapeutic benefits extended beyond patients with diabetes.

DAPA-HF demonstrated that dapagliflozin reduced worsening heart failure or cardiovascular death in patients with heart failure with reduced ejection fraction (HFrEF), irrespective of diabetes status. EMPEROR-Reduced demonstrated similar benefits with empagliflozin in HFrEF. Subsequently, EMPEROR-Preserved and DELIVER extended the evidence to patients with preserved or mildly reduced ejection fraction. [1–4]

The renal evidence has been equally transformative. CREDENCE established renal protection with canagliflozin in patients with diabetic kidney disease, while DAPA-CKD and EMPA-KIDNEY demonstrated benefits across broader CKD populations, including patients without diabetes. [5–7]

Current diabetes guidelines therefore recognize SGLT2 inhibitors as important agents for reduction of cardiovascular and renal risk. The 2026 American Diabetes Association Standards of Care recommend an SGLT2 inhibitor with demonstrated benefit for people with T2DM and CKD, with initiation at an estimated glomerular filtration rate (eGFR) of ≥20 mL/min/1.73 m² in appropriate patients. The same guidance recommends proven SGLT2 inhibitor therapy for individuals with T2DM and established heart failure with preserved or reduced ejection fraction. [8,9]

The therapeutic evolution of SGLT2 inhibitors raises an important pharmacotherapeutic question: how can a class initially developed to reduce blood glucose produce clinically meaningful benefits in the heart and kidney, including in people without diabetes?

This review therefore examines the pharmacological basis and mechanisms of SGLT2 inhibition, established cardiovascular and renal applications, emerging therapeutic areas, major clinical trials, safety considerations, patient counselling and future research directions.

2. Pharmacological Basis of SGLT2 Inhibition

Glucose is freely filtered through the glomerulus and is normally almost completely reabsorbed in the proximal renal tubule. SGLT2, expressed predominantly in the early proximal tubule, is responsible for the majority of filtered glucose reabsorption. SGLT1 contributes to glucose recovery in the more distal proximal tubule.

SGLT2 transports glucose together with sodium across the apical membrane of proximal tubular epithelial cells. Inhibition of this transporter reduces sodium-glucose reabsorption and increases urinary glucose and sodium excretion.

The resulting glucosuria contributes to a reduction in plasma glucose and glycated hemoglobin. Unlike insulin secretagogues, SGLT2 inhibitors do not directly stimulate pancreatic insulin secretion and therefore have a relatively low intrinsic risk of hypoglycemia when used alone.

Several SGLT2 or SGLT-related inhibitors are used clinically, including dapagliflozin, empagliflozin and canagliflozin. Ertugliflozin is another selective SGLT2 inhibitor used for diabetes management. Sotagliflozin inhibits both SGLT1 and SGLT2 and has also generated important cardiovascular and heart-failure evidence.

The clinical evidence and regulatory indications vary between individual agents and jurisdictions. Therefore, class effects should not automatically be interpreted as identical regulatory indications for every drug.

Table 1. Major SGLT2/SGLT-related inhibitors

3. Mechanisms of Action Beyond Glycemic Control

The benefits of SGLT2 inhibitors cannot be explained solely by urinary glucose excretion. Multiple complementary mechanisms are proposed.

SGLT2 inhibition increases urinary sodium and glucose excretion. Increased osmotic diuresis promotes fluid loss, while natriuresis reduces sodium retention. These effects may decrease plasma volume and venous congestion, particularly relevant to heart failure.

In diabetes, increased proximal tubular sodium-glucose reabsorption reduces sodium delivery to the macula densa. This can alter tubuloglomerular feedback and contribute to increased intraglomerular pressure. SGLT2 inhibition increases sodium delivery to the macula densa and restores tubuloglomerular feedback. The resulting afferent arteriolar response reduces intraglomerular pressure and may contribute substantially to renoprotection.

SGLT2 inhibition is associated with an initial modest decline in eGFR in many patients, followed by slower long-term loss of kidney function. This early change is generally interpreted as reflecting reduced intraglomerular pressure rather than structural kidney injury.

SGLT2 inhibitors generally produce modest reductions in blood pressure through combined natriuretic, diuretic and vascular mechanisms. They also produce modest weight reduction through urinary glucose loss and altered energy balance.

SGLT2 inhibition may alter myocardial substrate utilization, increase ketone-body availability, influence cytosolic sodium and calcium handling, and affect mitochondrial function. Experimental and clinical studies also suggest effects on oxidative stress and inflammatory signaling. SGLT2 inhibitors may increase urinary uric acid excretion and serum hematocrit through effects on urate handling and erythropoiesis/iron metabolism.

Table 2. Proposed mechanisms beyond glycemic control

4. Cardiovascular Applications

The cardiovascular benefits of SGLT2 inhibitors represent one of the most important developments in modern cardiorenal pharmacotherapy. Early cardiovascular outcome trials in T2DM demonstrated reductions in heart-failure hospitalization, leading to dedicated HF trials.

In DAPA-HF, dapagliflozin significantly reduced the composite of worsening heart failure or cardiovascular death in patients with HFrEF. The primary outcome occurred in 16.3% of patients receiving dapagliflozin compared with 21.2% receiving placebo, corresponding to a hazard ratio of 0.74. Benefits were consistent in patients with and without diabetes. [1]

EMPEROR-Reduced similarly demonstrated that empagliflozin reduced cardiovascular death or hospitalization for HF in HFrEF. [2]

EMPEROR-Preserved randomized 5,988 patients with HF and ejection fraction >40% to empagliflozin or placebo. The primary outcome occurred in 13.8% versus 17.1%, corresponding to a hazard ratio of 0.79. The effect was mainly driven by reduced hospitalization for HF and was consistent regardless of diabetes status. [3]

DELIVER subsequently evaluated dapagliflozin in patients with HF and ejection fraction >40% and demonstrated a reduction in the composite of worsening HF or cardiovascular death. [4]

These trials support the role of SGLT2 inhibitors across the heart-failure spectrum. Their benefits in patients without diabetes indicate that mechanisms beyond glucose lowering are clinically important.

Table 3. Major cardiovascular outcome trials

5. Renal Applications

Diabetic kidney disease is a major complication of T2DM and an important cause of CKD and kidney failure. SGLT2 inhibitors have added a major therapeutic pathway for renal protection.

The CREDENCE trial evaluated canagliflozin in patients with T2DM, CKD and substantial albuminuria receiving renin-angiotensin system blockade. Canagliflozin significantly reduced the primary composite of kidney failure, doubling of serum creatinine, or renal/cardiovascular death. [5]

DAPA-CKD enrolled patients with CKD with and without T2DM. Dapagliflozin significantly reduced the risk of the composite renal/cardiovascular outcome. The inclusion of patients without diabetes demonstrated that renoprotection is not simply a consequence of improved glycemic control. [6]

EMPA-KIDNEY further expanded the evidence for empagliflozin in CKD, including patients without diabetes and those with lower levels of albuminuria. [7]

Current ADA 2026 guidance recommends an SGLT2 inhibitor with demonstrated benefit in people with T2DM and CKD at eGFR ≥20 mL/min/1.73 m² and recommends continuation when tolerated until kidney failure. [8]

The glucose-lowering effect decreases as kidney function declines; however, cardiovascular and renal benefits may persist at lower eGFR levels. This distinction is important in pharmacotherapy: reduced glucose-lowering efficacy does not imply loss of cardiorenal benefit.

Table 4. Major renal outcome trials

6. Cardiorenal-Metabolic Therapeutic Role

The increasing convergence of diabetes, CKD, HF and obesity has led to the concept of cardiorenal-metabolic disease. SGLT2 inhibitors influence several components of this interconnected disease network.

In the kidney, they reduce intraglomerular pressure and slow CKD progression. Through natriuresis and osmotic diuresis, they modify volume status. In the heart, they reduce congestion and HF hospitalization. Metabolically, they produce glucosuria, modest weight reduction and altered substrate utilization. They may also influence blood pressure, uric acid, inflammation and oxidative stress.

This multidimensional activity distinguishes SGLT2 inhibitors from traditional glucose-lowering therapies.

7. Emerging Therapeutic Applications

Metabolic dysfunction-associated steatotic liver disease (MASLD) is strongly associated with obesity, insulin resistance, T2DM and cardiovascular disease. SGLT2 inhibitors have demonstrated reductions in body weight, glycemic exposure and, in some studies, liver enzymes and measures of hepatic steatosis. Potential mechanisms include reduced caloric availability, improved insulin sensitivity, weight reduction and altered lipid metabolism. However, evidence for histological improvement and prevention of clinically significant liver outcomes remains less definitive than evidence for HF and CKD.

SGLT2 inhibitors produce modest weight reduction but are substantially less potent than dedicated modern anti-obesity pharmacotherapies. Their role in obesity is therefore likely to be as part of comprehensive cardiometabolic management.

SGLT2 inhibitors may increase urinary uric acid excretion and reduce serum urate. This is of interest in metabolic syndrome, CKD and cardiovascular disease, although they should not currently be regarded as substitutes for established urate-lowering therapy.

SGLT2 inhibitors can increase hematocrit and may influence erythropoietin and iron metabolism. These effects are scientifically important but do not make SGLT2 inhibitors conventional treatments for anemia.

SGLT2 inhibitors have also been explored in polycystic ovary syndrome because of effects on weight, glucose metabolism and insulin resistance. Early studies are promising but limited, and pregnancy-related safety considerations are important.

Changes in urinary glucose, sodium, volume and uric acid handling have prompted investigation of SGLT2 inhibitors in nephrolithiasis. Evidence remains insufficient to recommend them specifically for kidney-stone prevention.

Table 5. Emerging applications

8. Safety and Adverse Effects

SGLT2 inhibitors are generally well tolerated, but their mechanism produces characteristic adverse effects. Genital mycotic infections are the most characteristic class effect. Patients should receive counselling regarding genital hygiene and early recognition of symptoms.

Volume depletion and hypotension may occur because of osmotic diuresis and natriuresis, particularly in older adults and patients taking loop diuretics. Assessment of volume status and concomitant therapy is important.

Diabetic ketoacidosis is uncommon but clinically important. SGLT2 inhibitors can produce DKA with only modestly elevated blood glucose. Risk factors include prolonged fasting, acute illness, severe carbohydrate restriction, dehydration, alcohol intake, insulin deficiency and perioperative stress.

An early reduction in eGFR may occur after initiation and usually reflects hemodynamic changes. A large or persistent decline requires clinical evaluation.

Hypoglycemia risk is low when SGLT2 inhibitors are used alone but may increase with insulin or insulin secretagogues.

Fournier's gangrene is very rare but serious. Patients should seek urgent medical attention for severe genital or perineal pain, swelling, fever or systemic symptoms.

Early concerns regarding amputation and fracture risk were particularly associated with canagliflozin. Subsequent evidence has been more nuanced, and baseline patient characteristics should be considered.

Table 6. Adverse effects and management

9. Drug Interactions and Clinical Considerations

SGLT2 inhibitors have relatively few classical pharmacokinetic drug interactions, but clinically important pharmacodynamic interactions exist.

Concurrent loop or thiazide diuretics may increase volume depletion. In patients who are clinically euvolemic, diuretic requirements may need reassessment.

Combination with insulin or insulin secretagogues may increase hypoglycemia risk, and adjustment of concomitant therapy may be appropriate in selected patients.

The additional blood-pressure-lowering effect may require monitoring in patients receiving multiple antihypertensive agents.

SGLT2 inhibitors are frequently used alongside ACE inhibitors or ARBs in CKD. Their mechanisms are complementary, although renal function and volume status should be monitored.

Patients receiving medications that can impair renal perfusion, particularly in the presence of dehydration, require appropriate clinical assessment.

10. Perioperative and Acute-Illness Management

One of the most important practical issues is temporary interruption during situations associated with increased DKA risk.

SGLT2 inhibitors should generally be withheld before major surgery according to current local prescribing guidance and restarted only when the patient is clinically stable, adequately hydrated and eating normally.

Temporary interruption may also be appropriate during severe acute illness, prolonged fasting or significant dehydration. Patients should receive clear sick-day counselling.

11. Patient Counselling

Patient education is essential for safe and effective therapy. Patients should understand administration, hydration requirements, genital hygiene, symptoms of DKA, sick-day instructions, perioperative interruption, foot care where relevant, and the increased hypoglycemia risk when SGLT2 inhibitors are combined with insulin or sulfonylureas.

Patients should also be instructed to report severe or persistent urinary or genital symptoms and symptoms suggestive of ketoacidosis.

Table 7. Patient-counselling checklist

12. Special Populations

Older adults may derive substantial cardiovascular and renal benefit but can be more vulnerable to volume depletion, hypotension and genitourinary adverse effects. Treatment should be individualized according to renal function, blood pressure, frailty and concomitant medications.

Patients with CKD may benefit even when glucose-lowering efficacy is reduced at lower eGFR. Patients with HF may receive SGLT2 inhibitor therapy irrespective of diabetes status when supported by the specific agent's approved indication and guidelines.

SGLT2 inhibitors are not routine therapies during pregnancy because of limited human safety data and concerns arising from developmental kidney biology. They should not be used casually in pregnancy.

Temporary discontinuation may be appropriate during severe illness, fasting, dehydration or other situations associated with increased DKA risk.

13. Major Clinical Trials and Evidence Synthesis

The clinical evidence for SGLT2 inhibitors is supported by a large body of randomized controlled trials. EMPA-REG OUTCOME, CANVAS and DECLARE-TIMI 58 established cardiovascular and HF signals in T2DM. CREDENCE, DAPA-CKD and EMPA-KIDNEY established renal protection across diabetic and non-diabetic CKD populations. DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved and DELIVER established benefits across the HF spectrum.

A 2024 systematic review and meta-analysis across CKD populations found reductions in mortality, cardiovascular death, kidney failure and hospitalization for HF, with no credible subgroup interaction based on diabetes status, HF status, eGFR or albuminuria. Large meta-analyses across the cardiometabolic spectrum have also demonstrated consistent reductions in HF hospitalization.

Table 8. Landmark SGLT2 inhibitor trials

14. Pharmacotherapeutic Positioning

The appropriate role of SGLT2 inhibitors depends on the patient's dominant clinical risk.

In T2DM with CKD, an SGLT2 inhibitor with demonstrated renal benefit should be considered as part of comprehensive CKD and cardiovascular risk reduction.

In T2DM with HF, an SGLT2 inhibitor with demonstrated HF benefit should be considered independent of the need for additional glucose lowering.

In HF without diabetes, SGLT2 inhibitors can provide HF benefit when clinically indicated.

In CKD without diabetes, evidence from DAPA-CKD and EMPA-KIDNEY supports selected SGLT2 inhibitors.

In patients primarily seeking weight loss, SGLT2 inhibitors should not be regarded as first-line dedicated anti-obesity drugs.

Table 9. Practical pharmacotherapeutic positioning of SGLT2 inhibitors